GlassScriptPhysician profile
Saliatou Jordan
NPI 1023495942
$1,765.52
in general payments reported to CMS, 2019-2025
24 companies · $192 in 2025
The $192 reported for 2025 was more than what a typical Obstetrics provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $57.21 · 2021: $205 · 2022: $616 · 2023: $297 · 2024: $200 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $688.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $283.66 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $160.39 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $147.69 | 2021-2024 | |
| Organon LLC | $123.38 | 2022-2025 | Nexplanon |
| Aspira Women'S Health INC | $113.00 | 2022-2023 | Ova1 |
| Sumitomo Pharma America, INC. | $109.69 | 2023-2024 | Myfembree |
| Exeltis, USA INC. | $101.91 | 2022-2024 | Slynd |
| Renovia INC | $84.77 | 2019 | |
| Coopersurgical, INC. | $72.17 | 2020-2023 | Paragard T 380a |
| Therapeuticsmd, INC. | $69.91 | 2019-2022 | |
| Astellas Pharma US INC | $66.80 | 2023-2025 | Veozah |
| Shield Therapeutics INC | $64.50 | 2023-2025 | Accrufer |
| Myovant Sciences INC. | $61.36 | 2021-2022 | |
| Sage Therapeutics, LLC | $57.91 | 2022-2025 | Zurzuvae |
| Gynesonics, INC. | $46.94 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $36.14 | 2022-2023 | |
| Duchesnay USA Incorporated | $27.06 | 2019 | |
| Ethicon US, LLC | $23.80 | 2024 | Vistaseal, Prolene, Ethicon |
| Dynavax Technologies Corporation | $23.55 | 2025 | Heplisav-B |
| Allergan, INC. | $21.24 | 2020 | |
| Supernus Pharmaceuticals, INC. | $20.01 | 2025 | Qelbree |
| Seqirus USA INC | $18.91 | 2025 | Flucelvax |
| Smith+Nephew, INC. | $18.41 | 2022 | |
| Minerva Surgical, INC | $12.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saliatou Jordan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.